In vitro diagnostics is the basic principle of most laboratory activities. It influences three quarters of diagnostic decisions, affecting more than a half of direct costs of provided health care. Production, storing and distribution of in vitro diagnostic medical devices, as well as the laboratory diagnostic process itself (use of in vitro diagnostics) must strictly adhere to all legislative provisions relating to in vitro diagnostics. The article provides a detailed explanation of (i) Directive 98/79/CE on in vitro diagnostic medical devices, (ii) Act No. 22/1997 Coll. on technical requirements for products, (iii) Act No. 123/2000 Coll. on medical devices and (iv) Government Regulation No. 453/2004 on technical requirements for in vitro diagnostic medical devices.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Investigating the Shortcomings of the Flow Convergence Method for Quantification of Mitral Regurgitation in a Pulsatile In-Vitro Environment and with Computational Fluid Dynamics.
Cardiovasc Eng Technol
January 2025
Department of Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Germany.
The flow convergence method includes calculation of the proximal isovelocity surface area (PISA) and is widely used to classify mitral regurgitation (MR) with echocardiography. It constitutes a primary decision factor for determination of treatment and should therefore be a robust quantification method. However, it is known for its tendency to underestimate MR and its dependence on user expertise.
View Article and Find Full Text PDFTargeting mutant p53: Evaluation of novel anti-p53 monoclonal antibodies as diagnostic tools.
Sci Rep
January 2025
Department of Microbiology, Tumor and Cell Biology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
About 50% of all cancers carry a mutation in p53 that impairs its tumor suppressor function. The p53 missense mutation p53 (p53 in mice) is a hotspot mutation in various cancer types. Therefore, monoclonal antibodies selectively targeting clinically relevant mutations like p53 could prove immensely value.
View Article and Find Full Text PDFSuper-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma.
Sci Rep
January 2025
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, China.
Glioblastoma (GBM) is the most common intracranial malignancy, but current treatment options are limited. Super-enhancers (SEs) have been found to drive the expression of key oncogenes in GBM. However, the role of SE-associated long non-coding RNAs (lncRNAs) in GBM remains poorly understood.
View Article and Find Full Text PDFNovel and potent MICA/B antibody is therapeutically effective in mutant lung cancer models.
J Immunother Cancer
January 2025
Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
Background: Concurrent (STK11, KL) mutant non-small cell lung cancers (NSCLC) do not respond well to current immune checkpoint blockade therapies, however targeting major histocompatibility complex class I-related chain A or B (MICA/B), could pose an alternative therapeutic strategy through activation of natural killer (NK) cells.
Methods: Expression of NK cell activating ligands in NSCLC cell line and patient data were analyzed. Cell surface expression of MICA/B in NSCLC cell lines was determined through flow cytometry while ligand shedding in both patient blood and cell lines was determined through ELISA.
Correlation of SALL1 with CEUS Parameters and Immune Escape in Thyroid Carcinoma.
Biomed J
January 2025
Department of Medical imaging, Henan Provincial People's Hospital, No. 7, Weiwu Road, Jinshui District, Zhengzhou, Henan, 450000, China.
Background: Contrast-enhanced ultrasonography (CEUS) is widely used to diagnose thyroid carcinoma (TC), though its accuracy in differentiating malignant nodules is limited. We identified TC-associated differentially expressed genes (DEGs) and examined the impact of these genes, particularly SALL1, on immune escape mechanisms within TC cells.
Methods And Materials: DEG analysis was conducted on GSE65144 dataset to identify genes associated with TC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!